AIM BREAKFAST – 13th September 2016
Set Menu AIM:
Total number of AIM Companies (Incl Susp): 1004
Total number of AIM Companies trading: 989*
* As at 13 September 2016
Dish of the Day:
No Primary Today
No Primary Today
Off the Menu:
No AIM Leavers Today
No AIM Leavers Today
Set Menu ISDX Growth:
Total number of ISDX Growth Market Companies (Incl Susp): *
Total number of ISDX Growth Market Companies trading: *
* As at 13 September 2016
Dish of the Day:
Off the Menu:
What’s Cooking in the IPO Kitchen?
Shefa Yamin — Mining Weekly reports that the Israeli precious stone mining company is seeking a London listing this year
Jackpotjoy — Press reports Canadian online Bingo firm currently known as Intertain (TSX) to vote on an October IPO in London
Misys — The press reports that the Banking Technology provider owned by Vista Equity Partners is seeking a £5.5bn float in London
Bacanora Lithium — To list on AIM around 28 Sep as holding company for TSX listed Bacanora Minerals at £100m market cap
Venn Life Sciences* (VENN.L) 28p £16.9m
The growing Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients has appointed Allan Wood as chairman. He was previously Managing Director of Xansa Plc, an outsourcer of business processing solutions. He has extensive relevant experience in scaling businesses in health services and related sectors. Venn reports H1Jun16 results on 28 September.
STM Group (STM.L) 42p £24.95m
The cross border financial services provider has conditionally agreed to acquire London & Colonial Holdings for £5.285m, offering SIPP pension products in the UK and the equivalent in Gibraltar. It reported audited revenues in the twelve months to 30 September 2015 of £3.83 million, a loss before tax of £0.07 million and net assets of £4.8 million. The Board believes that STM will benefit from annualised cost synergies and economies of scale of approximately £750,000.
TP Group (TPG.L) 5.75p £24.3m
The specialist technology, engineering and managed solutions group, announced that TPG Engineering, the Group’s thermal systems company based in Greater Manchester, has been awarded a project to build a large steam condenser, to be installed next year at a chemical processing plant in the UK. The project, valued at close to £0.5m is a step change in scale for the subsidiary which hopes to establish itself as a supplier of end-to-end systems and solutions for critical applications.
InfraStrata (INFA.L) 1.37p £2.6m
The independent petroleum exploration and gas storage company’s subsidiary, InfraStrata UK Limited, has acquired an additional 25% equity stake in Islandmagee Storage, the developer of the gas storage facility in Northern Ireland, a JV with Moyle Energy Investments Limited. The Company is seeking to complete funding arrangements to sit alongside a grant of up to €4.024m from the EU in order to commence a Front-End Engineering Design and commercialisation process by year end.
Alliance Pharma (APH.L) 49.5p £232.5m
Alliance Pharma, has signed a further licensing and distribution agreement with Duchesnay Inc. of Canada for Diclectin, a proven product to treat nausea and vomiting of pregnancy. Alliance acquired UK rights to Diclectin in January 2015 and this additional agreement secures rights to launch the product in a further nine EU countries including Germany, France and Italy. The drug is well established in Canada and sales are growing quickly in the US.
Amryt Pharma (AMYT.L) 20.25p £42.2m
The clinical stage specialty pharma company focused on best in class treatments for orphan diseases, has been granted a US patent for its lead drug, Episalvan, in the treatment of Epidermolysis Bullosa. Episalvan, has already successfully demonstrated significantly faster healing both recent wounds & chronic wounds compared with standard care therapy. Amryt is now preparing for a pivotal phase III study. The company has also reported maiden interim results. Cash of €10.7m
K3 Business Technology Group (KBT.L) 332.5p £119.7m
Provider of mission-critical software, cloud solutions and managed services to the retail, manufacturing and distribution sectors has reported FYJun16 results. K3 Product licence revenues increased to c.25% of total licence sales. Revenues up 7% to £89.2m. Adjusted EPS up 21% to 23.5p. August £13m placing funded acquisition of DdD Retail. Upbeat outlook focussed on self help measures rather than blaming and mentioning Brexit, which appears to be the trend with other companies! FyJun17E forecasts put the shares on 12.4x and a yield of 0.6%.
Digital Barriers (DGB.L) 46p £75.96m
The specialist provider of visually intelligent solutions to the global surveillance, security and safety markets, announced the extension of its supplier contract, first agreed in August 2013, with BT Redcare. The increased level of commitment in the contract extension demonstrates the growing demand for the Group’s technologies in the UK public safety market. The extension secures a minimum order commitment of £2.0 million over three years.
Lombard Risk Management (LRM.L) 7.75p £31.05m
The provider of integrated collateral and regulatory reporting solutions is launching AgileCOLLATERAL, a cloud-based collateral management system which offers the functionality of its market-leading COLLINE solution in a modular, light touch delivery format. The AgileCOLLATERAL product is being launched now to help buy-side clients meet the stricter uncleared collateral margin requirements being phased in from around March 2017.
Westminster Group (WSG.L) 26.5p £23.08m
The supplier of managed services and technology based security solutions to governments and government agencies, NGOs and blue chip commercial organisations worldwide, announced that Sovereign Ferries’ Sierra Princess, has successfully completed her inaugural voyage. The service provides a much needed professional airport transfer service between the airport & the Capital Freetown (Sierra Leone) with a 20 minute crossing time and an efficient service around the capital and further afield.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX. If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.